THERAPY DOSSIER · th-35c099bdaf90

(-)-alpha-Bisabolol (BISA), a natural terpene

Nutraceutical · Sesquiterpene alcohol (levomenol / alpha-bisabolol); anti-inflammatory skin agent. No ChEMBL mechanism record.

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: Sesquiterpene alcohol (levomenol / alpha-bisabolol); anti-inflammatory skin agent. No ChEMBL mechanism record.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1096927 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: alpha-bisabolol; (-)-alpha-bisabolol; Dragosantol; Kamillosan
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04940520 ↗PHASE1completed

Alpha-bisabolol for Onychomycosis Treatment

Onychomycosis

Enrolment: 60 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31002923 ↗2019Reported benefit

(-)-α-Bisabolol reduces nociception and trigeminal central sensitisation in acute orofacial neuropathic pain induced by infraorbital nerve injury.

RatOtherSprague-Dawleymalen = n = 8 per group for behavioural testingoral (per oris)200 mg/kgadministered at post-operative day 7 after infraorbital nerve transection

Model: Infraorbital nerve transection (IONX), trigeminal neuropathic pain

Infraorbital nerve transection produced facial mechanical hypersensitivity unaffected by vehicle. Bisabolol 200 mg/kg orally significantly reversed the mechanical hypersensitivity for at least 6 h and reversed central sensitisation of medullary dorsal horn nociceptive neurons, restoring activation…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…